On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor being evaluated for the treatment of severe COVID-19 pneumonia, to receive a $300,000 grant from the State of Pennsylvania’s COVID-19 Vaccines,Treatments and Therapies Program.

The grant was awarded to RedHill’s partner, Apogee Biotechnology, from whom RedHill licensed opaganib, who will conduct the research being supported by the grant.